
Talphera Inc (TLPH) Stock Forecast & Price Target
Talphera Inc (TLPH) Analyst Ratings
Bulls say
Talphera Inc. has achieved a significant milestone with FDA approval to increase the maximum number of study sites from 10 to 14, which is anticipated to expedite the enrollment process for their NEPHRO CRRT study, targeting 166 patients. The ongoing collaboration with eight original large academic institutions is expected to enhance trial recruitment, as some institutions are projected to be among the highest enrollers. Moreover, Talphera's planned protocol modifications and the intention to submit a Prior Approval Supplement to adjust the patient requirement demonstrate a strategic approach toward fulfilling regulatory obligations and achieving study completion by year-end 2025.
Bears say
Talphera Inc. reported a net loss of $3.8 million for the second quarter of 2024, translating to a loss of $0.15 per share, reflecting ongoing financial challenges. The company’s decision to lower its 2024 operating expense guidance to a range of $19-$21 million from the previous $21-$23 million suggests difficulties in managing costs amidst mounting losses. Additionally, significant risks related to trial outcomes, FDA approvals, safety concerns, and funding acquisition pose further threats to the company's financial stability and growth prospects.
This aggregate rating is based on analysts' research of Talphera Inc and is not a guaranteed prediction by Public.com or investment advice.
Talphera Inc (TLPH) Analyst Forecast & Price Prediction
Start investing in Talphera Inc (TLPH)
Order type
Buy in
Order amount
Est. shares
0 shares